Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sofosbuvir + daclatasvir with or without ribavirin in Chinese treatment-experienced chronic hepatitis C
ChiCTR-OPC-15007449Phase 4Completed
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- May 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of sofosbuvir, daclatasvir and ribavirin in hepatitis C virus infection (3 arms), sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoint: HCV RNA. Started May 2015; status: completed.
02
Drugs
sofosbuvirdaclatasvirribavirin
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on ChiCTR-OPC-15007449.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OPC-15007449.